Evidence mapPaperPMID 35736259Full record

ReviewMembranes2022

An Updated View of the Importance of Vesicular Trafficking and Transport and Their Role in Immune-Mediated Diseases: Potential Therapeutic Interventions.

Miguel A Ortega, Oscar Fraile-Martinez, Cielo Garcia-Montero, Miguel Angel Alvarez-Mon, Ana Maria Gomez-Lahoz, Agustin Albillos, Guillermo Lahera, Javier Quintero, Jorge Monserrat, Luis G Guijarro and 1 more

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Membranes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06158152 (A Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Systemic Effect on Immunoinflammatory and Metabolic Status of an Oral Supplementation With AM3 in Patients With Metabolic Syndrome.), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06158152 narecruitingnot on this mapstarted 2024, after this paper: background citation

A Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Systemic Effect on Immunoinflammatory and Metabolic Status of an Oral Supplementation With AM3 in Patients With Metabolic Syndrome.

TypeinterventionalSponsorIndustrial Farmacéutica Cantabria, S.A.Ran2024 to 2026Enrolled48ConditionsMetabolic SyndromeArmsAM3 + Probiotic, Placebo, AM3
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Extracellular Vesicles as Biomarkers of Pregnancy Complications.International journal of molecular sciences · 2024
    Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Inhibition of the Exocyst Complex Attenuates the LRRK2 Pathological Effects.International journal of molecular sciences · 2023
    Article
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Miguel A OrtegaDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Spain.ORCID 0000-0003-2588-1708
Oscar Fraile-MartinezDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Spain.ORCID 0000-0002-4494-6397
Cielo Garcia-MonteroDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Spain.ORCID 0000-0001-6016-7855
Miguel Angel Alvarez-MonDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Spain.
Ana Maria Gomez-LahozDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Spain.
Agustin AlbillosDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Spain.
Guillermo LaheraDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Spain.ORCID 0000-0002-6152-3564
Javier QuinteroDepartment of Legal Medicine and Psychiatry, Complutense University, 28040 Madrid, Spain.
Jorge MonserratDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Spain.ORCID 0000-0003-1775-4645
Luis G GuijarroRamón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.
Melchor Alvarez-MonDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Spain.ORCID 0000-0003-1309-7510
Universidad de Alcalá · ESInstituto Cajal · ESUniversidad Complutense de Madrid · ES

Funding

Comunidad de Madrid B2020/MITICAD-CMNIMHD NIH HHS L60 MD003804
6 · The paper itself

Abstract

Cellular trafficking is the set of processes of distributing different macromolecules by the cell. This process is highly regulated in cells, involving a system of organelles (endomembranous system), among which are a great variety of vesicles that can be secreted from the cell, giving rise to different types of extracellular vesicles (EVs) that can be captured by other cells to modulate their function. The cells of the immune system are especially sensitive to this cellular traffic, producing and releasing different classes of EVs, especially in disease states. There is growing interest in this field due to the therapeutic and translational possibilities it offers. Different ways of taking advantage of the understanding of cell trafficking and EVs are being investigated, and their use as biomarkers or therapeutic targets is being investigated. The objective of this review is to collect the latest results and knowledge in this area with a specific focus on immune-mediated diseases. Although some promising results have been obtained, further knowledge is still needed, at both the basic and translational levels, to understand and modulate cellular traffic and EVs for better clinical management of these patients.

Indexed as

cellular trafficexosomesextracellular vesiclesimmune-mediated diseasestherapeutic applications

Identifiers

PMID35736259
PMCPMC9230090
OpenAlexW4282046584

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.